In addition, Skillsoft provides various platform capabilities, such as open platform, custom channels and journeys, administrator-promoted content, and flexible assignments, tracking and in-depth reporting, training groups, and records management. Further, the company offers learning management systems and talent management software.
The company has seen a strong increase in insider buying over the last year, and with its current low price, more could be on the way.
Skillsoft stock has a target price of $7 at Barclays. The consensus price target is higher at $8.50, but the stock traded at just $3.05 on Friday.
SomaLogic
This stock was hit hard at the end of last year and looks to be clawing its way back. SomaLogic Inc. (NASDAQ: SLGC) operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow-offate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. It also offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples.
The company’s SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. SomaScan’s biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness and others.
The company’s solutions also include SomaSignal tests, which are research use only tests for clinical trial applications. It serves research and clinical customers, with a focus on pharmaceutical and biotechnology companies, as well as academic research institutions. It also facilitates drug development, analysis of clinical trials and new human biology insights by assessing protein-protein and protein-gene networks.
Cowen has set a $9 target price. The consensus target is $7.75. The stock traded at $3.60 on Friday.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no history or liquidity, and major Wall Street firms have research coverage.
Originally posted at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
